BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

352 related articles for article (PubMed ID: 30138940)

  • 1. Diagnostic Value of ER, PR, FR and HER-2-Targeted Molecular Probes for Magnetic Resonance Imaging in Patients with Breast Cancer.
    Jin YH; Hua QF; Zheng JJ; Ma XH; Chen TX; Zhang S; Chen B; Dai Q; Zhang XH
    Cell Physiol Biochem; 2018; 49(1):271-281. PubMed ID: 30138940
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Breast MRI background parenchymal enhancement as an imaging bridge to molecular cancer sub-type.
    Dilorenzo G; Telegrafo M; La Forgia D; Stabile Ianora AA; Moschetta M
    Eur J Radiol; 2019 Apr; 113():148-152. PubMed ID: 30927939
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Prognostic value of estrogen receptor, progesterone receptor and human epidermal growth factor receptor-2 in node positive breast cancer patients treated by mastectomy].
    Wang SL; Li YX; Song YW; Wang WH; Jin J; Liu YP; Liu XF; Yu ZH
    Zhonghua Zhong Liu Za Zhi; 2010 Jul; 32(7):520-5. PubMed ID: 21029696
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of ER, PR and HER-2/neu (C-erb B 2) reactivity pattern with histologic grade, tumor size and lymph node status in breast cancer.
    Azizun-Nisa ; Bhurgri Y; Raza F; Kayani N
    Asian Pac J Cancer Prev; 2008; 9(4):553-6. PubMed ID: 19256737
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic values of negative estrogen or progesterone receptor expression in patients with luminal B HER2-negative breast cancer.
    Park C; Park K; Kim J; Sin Y; Park I; Cho H; Yang K; Bae BN; Kim KW; Ahn S; Gwak G
    World J Surg Oncol; 2016 Sep; 14(1):244. PubMed ID: 27619909
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Clinical characteristics and survival in the operable breast cancer patients with different molecular subtypes].
    Zhang HM; Zhang BN; Xuan LX; Zhao P
    Zhonghua Zhong Liu Za Zhi; 2009 Jun; 31(6):447-51. PubMed ID: 19950556
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Human epidermal growth factor receptor 2 status correlates with lymph node involvement in patients with estrogen receptor (ER) negative, but with grade in those with ER-positive early-stage breast cancer suitable for cytotoxic chemotherapy.
    Bartlett JM; Ellis IO; Dowsett M; Mallon EA; Cameron DA; Johnston S; Hall E; A'Hern R; Peckitt C; Bliss JM; Johnson L; Barrett-Lee P; Ellis P
    J Clin Oncol; 2007 Oct; 25(28):4423-30. PubMed ID: 17906205
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunohistochemical evaluation of human epidermal growth factor receptor 2 and estrogen and progesterone receptors in breast carcinoma in Jordan.
    Almasri NM; Al Hamad M
    Breast Cancer Res; 2005; 7(5):R598-604. PubMed ID: 16168103
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of the Expression of Amine Oxidase Proteins in Breast Cancer.
    Sun WY; Choi J; Cha YJ; Koo JS
    Int J Mol Sci; 2017 Dec; 18(12):. PubMed ID: 29261141
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Breast cancer subtypes identified by the ER, PR and HER-2 status in Thai women.
    Chuthapisith S; Permsapaya W; Warnnissorn M; Akewanlop C; Sirivatanauksorn V; Prasarttong Osoth P
    Asian Pac J Cancer Prev; 2012; 13(2):459-62. PubMed ID: 22524806
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Presenting features of breast cancer differ by molecular subtype.
    Wiechmann L; Sampson M; Stempel M; Jacks LM; Patil SM; King T; Morrow M
    Ann Surg Oncol; 2009 Oct; 16(10):2705-10. PubMed ID: 19593632
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Breast cancer subtype approximated by estrogen receptor, progesterone receptor, and HER-2 is associated with local and distant recurrence after breast-conserving therapy.
    Nguyen PL; Taghian AG; Katz MS; Niemierko A; Abi Raad RF; Boon WL; Bellon JR; Wong JS; Smith BL; Harris JR
    J Clin Oncol; 2008 May; 26(14):2373-8. PubMed ID: 18413639
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association between tumour characteristics and HER-2/neu by immunohistochemistry in 1362 women with primary operable breast cancer.
    Huang HJ; Neven P; Drijkoningen M; Paridaens R; Wildiers H; Van Limbergen E; Berteloot P; Amant F; Vergote I; Christiaens MR
    J Clin Pathol; 2005 Jun; 58(6):611-6. PubMed ID: 15917412
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Breast cancers: MR imaging of folate-receptor expression with the folate-specific nanoparticle P1133.
    Meier R; Henning TD; Boddington S; Tavri S; Arora S; Piontek G; Rudelius M; Corot C; Daldrup-Link HE
    Radiology; 2010 May; 255(2):527-35. PubMed ID: 20413763
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hormonal Receptor, Human Epidermal Growth Factor and Its Association with Breast Cancer Tumor Characteristics in Albania.
    Pajenga E; Rexha T; Çeliku S; Ugrinska A; Bejtja G
    Cent Eur J Public Health; 2016 Sep; 24(3):171-175. PubMed ID: 27760283
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of triple-negative and estrogen receptor-positive/progesterone receptor-positive/HER2-negative breast carcinoma using quantitative fluorine-18 fluorodeoxyglucose/positron emission tomography imaging parameters: a potentially useful method for disease characterization.
    Basu S; Chen W; Tchou J; Mavi A; Cermik T; Czerniecki B; Schnall M; Alavi A
    Cancer; 2008 Mar; 112(5):995-1000. PubMed ID: 18098228
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Reliability of estrogen receptor, progesterone receptor and human epidermal growth factor receptor 2 expression in breast cancer evaluated by immunohistochemistry].
    Gu CS; Ying M; He YJ; Liu YQ; Dong B; Ouyang T; Lu AP
    Zhonghua Yi Xue Za Zhi; 2013 Aug; 93(32):2571-3. PubMed ID: 24351599
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 status in invasive breast cancer: a 3,198 cases study at National Cancer Center, China.
    Zhu X; Ying J; Wang F; Wang J; Yang H
    Breast Cancer Res Treat; 2014 Oct; 147(3):551-5. PubMed ID: 25234844
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Mammographic and pathological features of triple-negative breast cancer].
    Wen SY; Han YW; Ma XM; Zhang J; Cui WJ; Cao XC; Wang X
    Zhonghua Zhong Liu Za Zhi; 2012 Apr; 34(4):291-5. PubMed ID: 22781043
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enhancement parameters on dynamic contrast enhanced breast MRI: do they correlate with prognostic factors and subtypes of breast cancers?
    Kim JY; Kim SH; Kim YJ; Kang BJ; An YY; Lee AW; Song BJ; Park YS; Lee HB
    Magn Reson Imaging; 2015 Jan; 33(1):72-80. PubMed ID: 25179138
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.